SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer

PURPOSE: Identification of effective biomarkers for the benefit of endocrine treatment and understanding the molecular pathways that contribute to the development of resistance are of crucial importance to the management of luminal breast cancer. The amino acid transporter SLC1A5 has emerging import...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfarsi, Lutfi H., El Ansari, Rokaya, Craze, Madeleine L., Mohammed, Omar J., Masisi, Brendah K., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357718/
https://www.ncbi.nlm.nih.gov/pubmed/34282517
http://dx.doi.org/10.1007/s10549-021-06298-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357718/
https://www.ncbi.nlm.nih.gov/pubmed/34282517
http://dx.doi.org/10.1007/s10549-021-06298-1

Ejemplares similares